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Abstract
Background: Alzheimer’s disease (AD) is characterized by the pathological deposition of amyloid-β (Aβ)
protein-containing plaques. Microglia and astrocytes are commonly attracted to the plaques by an unknown
mechanism that may involve cell adhesion. One cell adhesion family of proteins, the cadherins, are widely
expressed in the central nervous system. Therefore, our study was designed to map the expression of cadherins in
AD mouse brains. A particular focus was on plaques because diverse mRNA-species were found in plaques and their
surrounding area in brains of AD patients.
Methods: In this study, we used in situ hybridization to visualize cadherin expression in brains of two mouse models
for AD (APP/PS1 and APP23).
Results: A variable number of plaques was detected in transgenic brain sections, depending on the probe used. Our
first impression was that the cadherin probes visualized specific mRNA expression in plaques and that endogenous
staining was unaffected. However, control experiments revealed unspecific binding with sense probes. Further
experiments with variations in probe length, probe sequence, molecular tag and experimental procedure lead
us to conclude that cRNA probes bind generally and in an unspecific manner to plaques.
Conclusions: We demonstrate unspecific binding of cRNA probes to plaques in two mouse models for AD.
The widespread and general staining of the plaques prevented us from studying endogenous expression of cadherins in
transgenic brain by in situ hybridization.
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Background
With more than 25 million people affected worldwide, AD
is one of the most common age-dependent neurodegener-
ative disorders [1]. Its pathological hallmarks are plaques
and neurofibrillary tangles in the brain. Plaques represent
protein accumulations, which mostly contain Aβ peptides.
Commonly, plaques are surrounded by dying neurons and
neuroglia, like microglia and astrocytes [2–4]. The mech-
anism, by which microglia are attracted by aggregated Aβ
and attach to the plaques, is unknown. One possibility is
that cell adhesion molecules play a crucial role. Cadherins,
a family of calcium-depended cell adhesion proteins, are
widely expressed in the central nervous system. They play
an essential role in the formation and organization of the
nervous system [5–7]. Studies on post-mortem brains of
AD patients revealed that not only the protein, but also
the mRNA of the Aβ precursor protein (APP) is present
in senile plaques [8]. Ginsberg and colleagues [9, 10] pro-
vided evidence for diverse mRNA species in plaques and
in their surrounding area by the use of in situ hybridiza-
tions. In further studies, it was shown that the mRNA for
APP was present in the diffuse and immature state of the
plaque and that its mRNA regulation is altered [11].
The aim of the present study was to investigate the ex-
pression of multiple types of cadherins and to detect
possible alterations in brains from mouse models of AD.
We used the in situ hybridization technique to map
* Correspondence: Nicole.Hertel@med.uni-jena.de
Institute of Anatomy I, Friedrich Schiller University School of Medicine, Jena
University Hospital, 07743 Jena, Germany
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schaarschuch et al. Journal of Negative Results in BioMedicine  (2016) 15:22 
DOI 10.1186/s12952-016-0065-9
mRNA expression in the brain and other organs. With
this very popular and highly useful method, we ob-
tained plaque staining of different intensities, depend-
ing on the individual probe used. The initial conclusion
drawn from this differential staining pattern was that
the cadherin probes bind to plaques in a specific man-
ner. However, careful control experiments, including
the use of sense probes, demonstrated that the plaque
staining was unspecific. Additional controls with probes
that varied in length, sequence and the molecular tag,
confirmed the unspecific character of the RNA probe
binding to the plaques.
Methods
Animals
All procedures were performed in accordance with insti-
tutional guidelines and national laws on the treatment of
animals in research. We used the minimum number of
animals necessary to produce reliable scientific data.
For the present study, 6 hemizygous APP/PS1 mice
(all female) and 4 wild-type littermates (2 female and 2
male) were used. Differences in the expression patterns
between the genders were not detected. In the present
study, we show results for advanced amyloidosis at
6 months of age and for a severe state at 12 months of
age only. Data for 3-months and 9-months old mice are
not provided in the present work (unpublished data) in
order to avoid repetitions of similar results. In addition,
brains from 18.5-months old APP23 mutant mice (one
wild-type and two hemizygous animals; all female) were
used. Both mouse lines (kindly provided by Dr. Christoph
Kaether, Leibniz Institute of Age Research/Fritz Lipmann
Institute, Jena, Germany) have a C57BL/6 background and
were originally generated by the groups of Dr. Mathias
Jucker and Dr. Matthias Staufenbiel [12;13]. In the APP/
PS1 line, human KM670/671NL-mutated APP (= Swedish
double mutation) and L166P-mutated PS1 are coex-
pressed under the murine Thy-1 promotor. In this muta-
tion, amyloid deposits can be detected from 2–4 months
of age onward [12]. Mice of the APP23 line express the
same Swedish mutated APP under a murine Thy-1
promoter and plaque deposition starts to develop at 6–8
months of age [13].
Cloning of cDNA fragments of Pcdh8
Template RNA was isolated from the brain of a male
C57/BL6J adult mouse by using TRIzol reagent ac-
cording to the manufacturer’s instructions (Invitrogen,
Darmstadt, Germany). Obtained RNA concentration
was measured by a spectrophotometer.
Primer pairs for shortened Pcdh8 probes were de-
signed by using the Lasergene® Genomics Suite Software
(DNASTAR®, Madison, WI). In order to obtain fragment
1 (F1), which contains the first 812 bp of the open read-
ing frame, the following primers were used: Forward:
ATT TAG TCT CTG CTG GGT GCT CTC and reverse:
GGG CGC CGA AGG TGA AC. Another primer pair
(forward: AGG CCC GGG ATG CTG ACG AA, and
reverse: GAC GCT CTG CAA CCC TAC TGT) was
used to obtain a second fragment (F2), which repre-
sents the last 848 bp of the open reading frame.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) was performed with the ONE Step RT-PCR Kit
(Qiagen, Hilden, Germany) with the following param-
eters: Reverse transcription at 50 °C for 30 minutes,
inactivation of the transcriptase at 95 °C for 15 mi-
nutes, followed by 30 cycles of amplification (denatur-
ing for 45 seconds at 94 °C, annealing for 45 seconds
at 50 °C for F1 and 60.2 °C for F2, and extension for
1.5 minutes at 72 °C). The correct size of the generated
fragments was verified by agarose gel electrophoresis.
Fragments were eluted by MinElute Extraction Kit
(Qiagen) and cloned into a customized pCR®II-TOPO
vector by using the TOPO TA Cloning Kit (Invitrogen),
following the manufacturer’s instructions. Successfully in-
tegrated fragments were sequenced by a commercial com-
pany (Eurofins MWG Operon, Ebersberg, Germany) by
using specific internal primers. Sequences were verified by
using the NCBI-BLAST program [14].
cRNA probe generating
The plasmids listed in Table 1 were used as templates
for the in vitro synthesis of cRNA probes that were
Table 1 Plasmids used for generating cRNA probes
Name Plasmid Position of sequence Accession number Reference
mouse Cdh2 bMN3-KS+ mouse N-Cdh 333–1313 NM_007664.4 [27]
mouse Cdh11 BSSK11 452–2840 D31963 [28]
mouse Cux-2 pBC SK Cux2 5’ 737–1895 U45665 [29, 30]
mouse ER81 BSK-mouse er81 668–3168 NM018781 [31]
mouse Pcdh8 TOPOII-mPcdh8 201–1901 NM001042726 [32]
mouse Pcdh10 mOLe10 full length U88549 [33]
chicken Pcdh10 pBSVSK-ΔN2257 2259–3899 AF334802 [34]
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labelled with either digoxigenin (DIG) or fluorescein
(Fluo). Nonradioactive sense and antisense probes were
produced with the DIG RNA Labeling Kit or Fluo RNA
Labeling Kit (Roche Diagnostics, Mannheim, Germany),
respectively, according to the manufacturer’s instruc-
tions. Quick Spin columns (Roche Diagnostics) were
used for purification of the probes. Their correct size
was verified by agarose gel electrophoresis.
Staining of sections
APP/PS1 mice were deeply anesthetized with chloro-
form and decapitated for brain dissection. APP23 mice
were anesthetized with an intraperitoneal overdose in-
jection of pentobarbital (300 mg/kg body weight) and
the brains were dissected. Collected brains were fresh
frozen in 2-methyl butane chilled to about −40 °C on
dry ice and stored at −80 °C. For cryosectioning, frozen
brains of APP/PS1 and APP23 were embedded in
Tissue-Tek® OCT™ compound (Sakura Finetek
Germany, Staufen, Germany), cut at 20 μm thickness
on a refrigerated microtome and collected on SuperFrost/
Plus slide glasses (Menzel, Braunschweig, Germany). To
obtain a neuroanatomical overview, thionin staining was
carried out on adjacent sections within each brain series,
as described previously [15].
Immunohistochemistry
Single-label immunohistochemistry for Aβ
Brain sections were fixed in 4% formaldehyde (FA) di-
luted in phosphate-buffered saline (PBS) at 4 °C for
30 minutes and subsequently washed with PBS. For
blocking of unspecific antibody binding, sections were
incubated for 1 hour at room temperature with 2%
sheep serum and 1% Triton-X diluted in PBS. Primary
antibody α-3552 against Aβ (derived from rabbit serum;
a kind gift of Dr. Christian Haass, University of Munich,
Munich, Germany) was diluted 1:1000 in blocking solu-
tion and applied overnight at 4 °C. Sections were again
washed with PBS and incubated with secondary antibody
Alexa Fluor® 488 α-rabbit IgG (Invitrogen) diluted
1:1000 in blocking solution, for three hours at room
temperature. Final differentiation was performed by PBS
washes. Brain sections were mounted in Mowiol solution
(Calbiochem-Novabiochem Corporation, La Jolla, USA).
Double-label immunohistochemistry for Protocadherin-10
(Pcdh10) and Aβ
All of the mentioned solutions were supplemented with
1 mM CaCl2 and 1 mM MgCl2. Frozen brain sections
were thawed for 30 minutes at 37 °C, followed by re-
trieval in HEPES-buffered salt solution (HBSS, pH 7.4)
and immediately put in ice-cold HBSS-buffer. Sections
were fixed in 4% PFA/HBSS for 30 minutes at 4 °C and
washed twice with Tris-buffered saline (TBS), followed
by TBS supplemented with 0.1% Triton X (TBT). There-
after, slides were incubated in blocking solution (3%
skim milk; 2% normal goat serum in TBT) for 1 hour at
room temperature. Primary antibodies α-Pcdh10 (5G10;
derived from rat serum; a kind gift of Dr. Shinshi
Hirano, Center for Developmental Biology (CDB),
RIKEN, Kobe, Japan.), diluted 1:300, and α-3552, diluted
1:1000, were applied in blocking solution overnight at
4 °C, followed by washing steps of TBS and TBT. As
secondary antibodies, Biotin-SP-conjugated AffiniPure
α-rat (dilution 1:300; Jackson ImmunoResearch, 112-
065-143) and Goat anti-Rabbit IgG (H + L) Cy5 (dilu-
tion:1:1000; Thermo Fisher Scientific, A10523) were
used in the same blocking solution and applied for
2 hours at room temperature. Brain slices were then
washed again with TBS and TBT and incubated with
Alexa Fluor® 488 conjugate-streptavidin (dilution 1:1000;
Thermo Fisher Scientific, S-11223) in blocking solution
for 2 hours at room temperature. After several washing
steps with TBS, sections were counterstained with
Hoechst 33342 (Thermo Fisher Scientific) to visualize
nuclei and mounted in Mowiol solution.
In situ hybridization
The in situ hybridization procedure followed estab-
lished protocols [15, 16]. Brain sections were fixed in
4% FA/PBS at 4 °C for 30 minutes followed by PBS
washes and Proteinase-K digestion (1 μg/ml in 100 mM
TRIS pH 8.0, 50 mM ethylenedinitrilotetra acetic acid dis-
odium salt dehydrate [EDTA]; Sigma-Aldrich, Steinheim,
Germany) for 5 minutes. After PBS-washing steps, post-
fixation for 30 minutes in 4% FA/PBS and washing in
DEPC-treated water, slides were treated with 0.25% acetic
anhydride/PBS. Subsequently, sections were washed with
PBS and then hybridized overnight in a humid chamber
with 1 μg/ml cRNA probe in hybridization solution
(50% formamide, 10 mM EDTA, 3× saline sodium cit-
rate buffer [SSC], 1× Denhardt’s solution, 10% dextran
sulfate, 42 μg/ml yeast tRNA, and 42 μg/ml salmon
testis DNA) at 70 °C. However, for the F1 and F2
probes, a hybridization temperature of 67 °C was
used. After hybridization, sections were washed with
5× SSC at room temperature, followed by incubation
in 5× SSC for 30 minutes at 60 °C. For the F1 and
F2 probes, all high temperature washing steps were
carried out at 57 °C. Afterwards, sections were incu-
bated in 50% formamide/2× SSC solution at 60 °C for
one hour. To remove unbound cRNA, sections were
washed with NaCl-TRIS-EDTA buffer and treated
with 20 μg/ml RNase A in the same buffer for 30 mi-
nutes, followed by another washing step with NaCl-
TRIS-EDTA buffer. Subsequently, brain sections were
again treated with 50% formamide/2× SSC at 60 °C
for 40 minutes and afterwards washed with 2× SSC at
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60 °C for 30 minutes. The ensuing washing steps
were carried out at room temperature in 0.1× SSC
for 30 minutes and PBS. For blocking unspecific bind-
ing reactions, brain slices were treated with 2% sheep
serum/PBS for one hour at room temperature. Sections
were then incubated overnight at 4 °C with alkaline
phosphatase-coupled anti-digoxigenin Fab fragments or
alkaline phosphatase-coupled anti-fluorescein Fab frag-
ments (Roche Diagnostics) diluted 1:2000 in 1% sheep
serum and 0.02% sodium azide in PBS. To reduce back-
ground staining, slides were washed with TRIS-buffered
saline and incubated in NTM solution (100 mM NaCl,
100 mM TRIS pH 9.5, 50 mM MgCl2) for ten minutes.
Labeled mRNA was visualized by incubating the sections
with the substrates 0.03% nitroblue tetrazolium salt
(Fermentas, St. Leon-Rot, Germany) and 0.02% 5-
bromo-4-chloro-3-indolyl-phosphate, ρ-toluidine salt
(Fermentas) in NTM solution for one to three days at
room temperature. The reaction was stopped by washing
in H2O, followed by a rinse with TE buffer. Staining was
differentiated by using ethanol and xylenes. Finally, slides
were mounted in Entellan (Merck, Darmstadt, Germany).
In situ hybridization without formamide
The procedure was the same as the one described
above, but we excluded formamide from all washing
steps, i.e. sections were treated in the 2× SSC solu-
tion only. However, formamide was kept in the
hybridization solution.
In situ hybridization with RNase pretreatment
Brain sections were pretreated with 10 μg/ml RNase A
in PBS for 30 minutes at 37 °C, followed by three washes
with PBS at 37 °C. RNase A was inactivated by incuba-
tion with 0.3 U/μl RiboLock (Fermentas) in PBS for
10 minutes at RT, followed by PBS washes. Subse-
quently, the in situ hybridization was performed exactly
as described above.
Photomicrograph production
Digital photomicrographs of the brain sections were
taken with a light transmission and fluorescence micro-
scope (BX40, Olympus) and a digital camera (DP70,
Olympus). Digitized fluorescence signal was converted
to grayscale pixel values by a computer. Contrast and
brightness of the images were adjusted for optimal dis-
play of the staining patterns by using the Photoshop
software (CS5, Adobe Systems).
For identification of different brain areas, neuroana-
tomical nomenclature and abbreviations, an adult mouse
brain atlas [17] was consulted.
Results
Cadherin in situ hybridization results in differential
plaque staining in AD mouse models
We analyzed the expression patterns of several cadherins
with antisense cRNA probes. In the present work, we
show exemplary staining patterns only for cadherin-2
(Cdh2), Cdh11, protocadherin-8 (Pcdh8) and Pcdh10 in
transgenic 12-months-old APP/PS1 mice and wild-type
littermates. In Fig. 1, results are compared with 18.5-
months-old transgenic and wild-type APP23 mice. The
overall staining pattern in wild-type mice was similar in
the two mouse strains and did not differ from the en-
dogenous staining patterns described before in wild-type
mice [16, 18, 19]. With the cRNA probes of mouse cad-
herins, we detected a high number of spot-like struc-
tures that were exclusively seen in the transgenic brains
in both AD mouse lines (Fig. 1g-j; q-t). Because the gen-
eral distribution of these spots was reminiscent of the
distribution of plaques described in AD mouse brains
previously [12, 13] and the spot-like staining was never
detected in wild-type sections (Fig. 1b-e; l-o), we tenta-
tively identified the spots as plaques. Remarkably, the
plaques varied prominently in number and staining in-
tensity between the cadherin probes. While Cdh2
(Fig. 1g; q) and Pcdh10 (Fig. 1 j; t) showed less wide-
spread plaque staining in transgenic AD mouse brains,
Cdh11 (Fig. 1h; r) and Pcdh8 (Fig. 1i; s) probes seemed
to detect a much greater number of plaques. Nissl stain-
ing of adjacent sections (Fig. 1a; f; k; p) revealed no dif-
ference in overall cytoarchitecture between the wild-type
and transgenic brains or between brains from the two
mouse strains. Because there was relatively little differ-
ence in the staining patterns between the two lines of
AD mouse models, the following results are described
for wild-type and transgenic APP/PS1 mice only.
Sense and antisense cRNA probes result in similar plaque
staining
Control experiments with sense cRNA probes of the
chosen cadherins revealed a high rate of plaque detec-
tion in transgenic APP/PS1 mice. This result suggested
unspecific plaque staining. To confirm this possibility,
adjacent frontal hippocampal sections of transgenic and
wild-type APP/PS1 mice were stained with sense and
antisense probes (Fig. 2). A Nissl stain of the hippocam-
pal formation revealed no neuroanatomical abnormal-
ities in transgenic mouse brain (Fig. 2a). Aβ staining of
plaques was restricted to transgenic brains (Fig. 2d) and
not observed in wild-type sections (Fig. 2g). Both sense
(Fig. 2e; f ) and antisense cRNA probes for cadherins
(Fig. 2d, c) stained plaque formations in similar number
and intensity in transgenic brains. For Cdh11, the anti-
sense probe (Fig. 2b) resulted in a normal endogenous
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staining pattern and, in addition, in a visualization of nu-
merous plaques. The same plaque staining was seen with
the sense probe for Cdh11, but no endogenous staining
was observed (Fig. 2e). Similar results were obtained for
Pcdh10 (Fig. 2c; f ), but overall plaque staining was less
intensive. To confirm that the binding of the sense
probes was not specific, wild-type sections were hybrid-
ized with Cdh11 sense probes (Fig. 2h) and Pcdh10 sense
probes (Fig. 2i), which yielded no endogenous signal.
Smaller cRNA probes for detection of the same cadherin
also show unspecific plaque staining
The sense and antisense cadherin probes used for the
above in situ hybridization studies were rather long
(>1200 bp). To study whether the unspecific plaque
binding of the probes depended on probe length or on
specific probe regions, we asked whether shorter (par-
tial) cRNA probes for the cadherin sequences resulted
in less or even absent unspecific plaque staining. For
this purpose, we generated two partial probes from
the open reading frame of Pcdh8 and hybridized them
with sections from APP/PS1 mice (Fig. 3). Fragment
1 detects the first 812 bp of the open reading frame while
fragment 2 hybridizes with the last 848 bp. For both anti-
sense probes (Fig. 3a; c), the brain sections revealed the
same endogenous staining as the longer Pcdh8 probe of
about 1700 bp (Fig. 1i). In addition, the corresponding
sense probes for fragment 1 (Fig. 3b) and fragment 2
(Fig. 3d) showed plaque staining similar to that described
for the longer probes of Cdh11 and Pcdh10 (Fig. 2e: f ).
Fig. 1 Nissl staining (a; f; k; p) and in situ hybridization of (proto-)cadherins in 12-months-old APP/PS1 wild-type mice (a-e) and transgenic mice
(f-j), as well as in 18.5-months-old APP23 wild-type mice (k-o) and transgenic mice (p-t). Nissl staining revealed no differences in cytoarchitecture
between the wild-type brains (a; k) and the transgenic brains (f; p). Transgenic brains only (g-j; q-t) showed staining of plaques by in situ hybridization
in both mouse lines, whereas the overall endogenous expression patterns were similar to that of wild-type brains. The asterisks in b; d; j; k; n; o; p; q; r;
s; t indicate artifacts that were induced during dissection of the brains (tissue tears) or collection of the sections on the glass slides (folds
and bubbles). Amy, amygdala; Cx, cerebral cortex; Hip, hippocampus; LV, lateral ventricle; tg, transgenic; Th, thalamus; wt, wild-type. Scale
bar in t = 1 mm (applies to all panels)
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Unspecific staining behavior is independent of the
detected RNA
We next asked whether the unspecific plaque staining is
a feature unique to probes detecting cell-adhesion mole-
cules like cadherins. Therefore, APP/PS1 wild-type and
transgenic sections were treated with probes for two
transcription factors, Cux2 and ER81 (Fig. 4). In wild-
type brains, the endogenous expression patterns for
Cux2 (Fig. 4a) and ER81 (Fig. 4b) did not differ from the
pattern described in the literature [20, 21]. The endogen-
ous staining was also visible on the transgenic sections.
In addition, strongly stained dot-like structures were ob-
served when brains were hybridized with antisense
probes (Fig. 4b; e). A treatment with sense probes showed
the same plaque staining but without endogenous staining
in the brain (Fig. 4c; f ).
Attempts to eliminate the unspecific binding properties
Because the unspecific plaque binding partially ob-
scured the endogenous staining pattern that was the
focus of our study, we attempted to reduce or elimin-
ate it (Fig. 5).
First, we considered the possibility that the digoxi-
genin tag mediated the unspecific binding of the probes
to the plaques. We therefore generated Pcdh10 probes
with a fluorescein tag and hybridized transgenic and
wild-type APP/PS1 brain sections using the same
hybridization procedure as above. The Pcdh10
Fig. 2 In situ hybridization of transgenic (a-f) and wild-type APP/PS1 mouse brains (g-i) at the age of 12 months. Plaque staining is obtained
exclusively in transgenic hippocampal formation with sense (e; f; h; i) and antisense (b; c) probes for Cdh11 and Pcdh10. Amyloid beta immunohis-
tochemistry confirmed the large number of plaques in the transgenic sections (d) with no staining visible in wild-type sections (g). The Nissl stain-
ing in (a) indicates a normal hippocampal cytoarchitecture in the transgenic brains. as, antisense probe; CA1-3, subdivision 1–3 of the cornu
ammonis; DG, dentate gyrus; s, sense probe; tg, transgenic; wt, wild-type. Scale bar in i = 1 mm (applies to all panels)
Fig. 3 In situ hybridization of Pcdh8 with partial sense and antisense probes in APP/PS1 transgenic mice at the age of 12 months. Fragment 1
(a; b) detects the sequence of the first ~ 810 bp from the open reading frame of protocadherin-8, while Fragment 2 (c; d) detects the last ~ 850 bp.
The asterisks in a; b; c; d indicate dissection artifacts (see legend to Fig. 1). Scale bar in d = 1 mm (applies to all panels)
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expression profile in the wild-type brain turned out to
be very similar to the one with the digoxigenin tag (com-
pare Fig. 5a to Fig. 1e). Moreover, the same staining pat-
tern for the two different tags was detected in transgenic
brain sections (compare Fig. 5b to Fig. 1j ), where pla-
ques were visualized in addition to the endogenous
staining. Again, when using the sense probe of Pcdh10-
fluorescein, the wild-type section showed no staining
(Fig. 5b) while the transgenic sections displayed plaque
staining only (Fig. 5g).
Second, we asked whether the unspecific binding
depended on the species from which the probe was
derived. Therefore, we hybridized transgenic and
wild-type sections with an antisense Pcdh10 probe
from chicken. In the sections from transgenic mouse
brain (Fig. 5h), plaques were visualized while no
staining was seen in the corresponding wild-type sec-
tion (Fig. 5c). As expected, endogenous staining was
not visualized in mouse brain with the chicken probe.
Thus, both mouse and chicken probes bind to pla-
ques in mouse sections.
Third, Pardue et al. [22] described that unspecific bind-
ing of radiolabeled oligonucleotides can be eliminated by
excluding formamide from the in situ hybridization pro-
cedure. We therefore modified the in situ hybridization
protocol and omitted formamide in the washing steps.
With the antisense probe for Pcdh8, weaker but specific
staining for Pcdh8 can be detected in wild-type sections of
6-months-old APP/PS1 mice (Fig. 5d). In the transgenic
brains of a littermate, the unspecific plaque staining was
still strong (Fig. 5i).
Forth, as a final proof that the overall plaque staining is
unspecific in our experiments, APP/PS1 transgenic and
wild-type brain sections were pretreated with RNase A.
This pretreatment completely abolished the visualization
of endogenous Pcdh8 expression in wild-type and trans-
genic sections (Fig. 5e; j), but did not eliminate the binding
of the probe to the plaques (Fig. 5j ).
Alternative experimental procedure to investigate
cadherin expression in plaques
In Additional file 1: Figure S1, we show a double label
immunohistochemistry of Pcdh10 and Aß on a section
from 6 months-old APP/PS1 transgenic mouse brain.
Aß (red) staining is widely distributed in plaque forma-
tions. Co-expression of Pcdh10 (green) in plaques is seen
in brain areas only that express Pcdh10 endogeneously
(e.g. cerebral cortex). Here, the mantle of the plaques
show diffuse co-expression while the dense core shows
staining for Aβ only (see insert in A). In areas that are
Pcdh10-negative, co-expression is not detected. Thus,
there is no ubiquitous, plaque-specific expression of
Pcdh10 protein. Unfortunately, only very few antibodies
against several cadherins are commercially available.
Therefore, it is not possible to investigate a large subset
of the cadherin superfamily by immunohistochemistry.
Discussion
Here, we describe the unspecific binding behavior of
RNA probes to plaques in transgenic brains of two
mouse models for AD. Due to the lack of binding
specificity, it was not possible to investigate the ex-
pression of cadherins in and around the plaques by
the use of in situ hybridization. Possible factors that
might contribute to the present results are discussed
in the following sections.
Fig. 4 Expression pattern of the transcription factors Cux2 and ER81
in brains of 12-months-old APP/PS1 transgenic (b; c; e; f) and
wild-type (a; d) mice. Labelled plaques are seen for both probes
with equal intensity for sense and antisense probes. The asterisks
in a and e indicate dissection artifacts (see legend to Fig. 1).
Scale bar in f = 1 mm (applies to all panels)
Schaarschuch et al. Journal of Negative Results in BioMedicine  (2016) 15:22 Page 7 of 10
Unspecific binding to highly compact cellular structures
Control experiments show that the number of detected
plaques was as high for sense probes as for antisense
probes. We assume that this result reflects unspecific
binding of the RNA probes. Unspecific binding of probes
used for in situ hybridization was initially described by
Higgs and Wilson [23] who found that probes got stuck
in brain areas of compact cell density, e.g. in piriform
cortex and hippocampus. The three-dimensional
structure of the plaques, which contain Aβ fibres, de-
graded neurons and microglia, can possibly result in a
similarly high density of cells and/or cellular debris,
which might attract RNA probes. Furthermore, it has
been found that the expression of APP is regulated
by RNA-binding proteins [24]. If these proteins are
located in and around the plaques, they might act like
adhesion traps for RNA. Such a general RNA binding
mechanism could explain why every probe that was
used in the present study attached to the plaques.
Maturation state of the plaque
Another factor that might affect RNA detection by in
situ hybridization is the state of plaque maturation.
Previously, Marcinkiewicz’ study on the detection of
mRNA for APP revealed that prominent hybridization
signal was obtained only for plaques at an early (dif-
fused) stage of plaque maturation [11]. The low signal
obtained in mature plaques lead the author to believe
that there was less amount of APP mRNA in mature
plaques. Alternatively, because RNA affinity may de-
pend on the plaque stage, we propose that early-stage
plaques with their loose structure might be more
prone to bind RNA in general. In the present study,
we found differential staining of plaques also in indi-
vidual brain sections. We assume that this differential
staining is due to the presence of both early and ma-
ture plaques in the sections.
Effect of endogenous expression on the staining intensity
of plaques
Whereas some probes stained nearly all plaques, other
probes tended to detect only a few plaques. This differ-
ential staining pattern was similar in both transgenic
mouse lines and contributed to our initial impression
that the staining patterns were specific for individual
cadherins. We offer the following possible explanations
for this finding: The reduced endogenous staining
might originate from differences in the time-course of
the substrate reaction between brain sections treated
with different probes. On the one hand, for cadherins
that are expressed at high levels in the brain, the spe-
cific staining will appear fast during the substrate reac-
tion, while the staining of plaques will emerge more
slowly. Thus, substrate reaction will be stopped early
when endogenous staining has appeared; plaque stain-
ing will be less intense. On the other hand, if endogen-
ous expression is weak, the specific staining will appear
more slowly, while the staining of plaques emerge fas-
ter, resulting in apparently more intense plaque staining
Fig. 5 a; b; f; g: Results from an attempt to eliminate unspecific plaque binding by using fluorescein-tagged sense (b; c) and antisense (a; f) probes
for Pcdh10. c; h: Results from using antisense probes for chicken Pcdh10. d; i: Antisense Pcdh8 staining without formamide in the washing buffers
on transgenic and wild-type sections of 6-months-old APP/PS1 mice. e; j: RNase pretreatment of brain sections before standard Pcdh8-in situ
hybridization on wild-type and transgenic brain section of 6-months-old APP/PS1. The asterisks in b; d; e; f; g; h; i indicate dissection artifacts
(see legend to Fig. 1). tg, transgenic; wt, wild-type. Scale bar in f = 1 mm (applies to all panels)
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when the substrate reaction is stopped. This possibility
could also explain why all sense probes tend to detect the
plaques: Due to the lack of specific binding, the substrate
reaction is stopped only after plaque staining has devel-
oped. Alternatively or in addition, the reduced endogen-
ous staining might also originate from the high number of
plaques, which may capture probes and therefore reduce
the amount of probe available for detection of endogenous
mRNA. A third possibility for the variation in plaque
staining may be a variation in hybridization efficiency of
the different probes. While some probes may tend to have
a higher binding affinity to their specific sequences, other
probes may show less binding specificity and therefore at-
tach more prominently to the plaques.
RNA probe length
In general, it is believed that shorter fragments of
RNA and DNA increase unspecific binding which
may explain why oligonucleotides with a length of
~30 bp adhere strongly to plaques, as shown in a
study of brain sections of AD patients [22]. Similar
results were obtained with biotinylated sense and
antisense oligonucleotides against Aβ [25]. In our
study, the initially used probes had lengths of more
than >1200 bp, with the aim to decrease unspecific
binding. However, all further experiments with varia-
tions in probe length (800─3400 bp) always showed
the same unspecific plaques staining. This finding
suggests that unspecific binding occurs irrespective of
probe length.
Type of the probe tag
Another possible cause for the binding of cRNA
probe to the plaques may be the molecular tag of the
probe, which might be prone for binding to plaques.
To detect the probe, we used digoxigenin, a steroid
with a large three-dimensional structure. Digoxigenin
is commonly used as a tag for in situ hybridization
and immunohistochemistry. To exclude the possibility
that digoxigenin caused the unspecific binding, we
generated a Pcdh10 probe with the same sequence
but with fluorescein, another commonly used molecu-
lar tag. This probe turned out to have the same affin-
ity to plaques as the digoxigenin-labelled probe,
although fluorescein has a different three-dimensional
structure. An investigation with radiolabeled oligo-
nucleotide probes showed similarly unspecific binding
to plaques on post-mortem tissue of AD patients
[22]. Therefore, we conclude that the attached tag has
no effect on the plaque binding.
Effect of formamide on the unspecific binding
In the study of Pardue and colleagues [22], several steps
were varied in the procedure to reduce unspecific
binding behavior. The only successful modification was
the elimination of formamide during the posthybridiza-
tion washing steps. Another in situ hybridization study
without formamide was successful in a different mouse
model for AD and was confirmed by Aβ counterstaining
[26]. We also excluded all formamide in the washing
steps but were not able to achieve a similar reduction of
unspecific binding. One reason might be that the
hybridization solution in our study still contained form-
amide. Without formamide in the hybridization solution,
the in situ hybridization failed in our hands.
Conclusions
Here we described the phenomenon of unspecific bind-
ing of cRNA probes to plaques in transgenic brains of
two mouse models for AD. Due to the interference by
unspecific probe adhesion, it was not possible to investi-
gate alterations in cadherin expression in the transgenic
mouse models for AD. One way to approach the investi-
gation of cadherin expression in transgenic AD-mouse
lines is the use of protein detection by immunohisto-
chemistry (Additional file 1: Figure 1).
Additional file
Additional file 1: Figure S1. Double-label immunohistochemistry for
Pcdh10 (green) and Aβ (red) on sections from 6-months old APP/PS1
transgenic brains (A). Negative control for an adjacent section (B) was per-
formed by excluding the primary antibodies from the staining procedure.
The asterisks in A and B show dissection artifacts (see legend to Fig. 1). The
insert in (A) shows a plaque at a higher magnification. Scale bar in B =
200 μm (applies to A, B). Scale bar in the insert = 100 μm. (TIF 27701 kb)
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